NFE2L2 and non-small cell lung carcinoma: CP-673451, which suppresses Nrf2 transcription through PI3K/Akt inhibition, downregulated platelet-derived growth factor receptorβ (PDGFRβ) and induced apoptosis in NSCLC cells, ultimately sensitizing them to cisplatin 105.